The recent deaths of four women in France have caused a rethinking of the connection between oral contraceptives and thromboembolism. The French authorities reacted by banning the pill involved (Diane-35; Bayer HealthCare Pharmaceuticals, Wayne, NJ) and were promptly taken to court, whereas other European countries have reevaluated their recommendations regarding which pills should be prescribed. Some experts maintain there is more than sufficient evidence on which to base clinical decisions; this knowledge was reviewed by Helmerhorst and Rosendaal.1
展开▼
